


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/376,430

Filed: August 18, 1999

For: **Cytokine Receptor Common
Gamma Chain Like**



Art Unit: 1646

Examiner: O'Hara, E.

Attorney Docket No.: PF466P1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject

application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AE listed on the attached form PTO 1449.

Copies of references AA-AE were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/263,626, filed March 5, 1999, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/263,626 for copies of references AA-AE.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding clone of the captioned application are related to: (1) SEQ ID NO:10291 in copending U.S. Patent application No. 08/798,074; and (2) SEQ ID NO:13633 in copending U.S. Patent application No. 09/504,576.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application.

Furthermore, Applicants do not waive any rights to appropriate action to establish


patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,


Dated: 4/17/2000


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

MMW/CB/ur

FORM PTO-1449

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**
(Use several sheets if necessary)Docket No. (Optional)
PF466P1Application Number
09/376,430Applicant
Moore et al.Filing Date
August 18, 1999Group Art Unit
1646**U.S. PATENT DOCUMENTS**

Examiner	Document Number	Date	Name	Class	SubCls	Filing Date

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	SubCls	Translation Yes/No
	AA 98/57989	12/23/98	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Genbank Entry, Accession No. X91553 (1996)
AC	Townsend et al., Journal of Allergy and Clinical Immunology, 99(1):16 (1997)
AD	Watson, et al., editors. The G-Protein Linked Receptor Facts Book. Academic Press, 350-355 (1994)
AE	Callard, R.E. et al., The Cytokine Facts Book, Academic Press, London 1994

Examiner

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.